Suivre
Abonner sanofi-aventis Group

sanofi-aventis Group

Filtre
  • 09.08.2011 – 14:55

    Sanofi Announces Nursing Recognition Program to Help Turn Caring Ideas Into Reality

    Paris (ots/PRNewswire) - -- Nurses Worldwide are Encouraged to Enter an Exciting Recognition Program Which Showcases Their Creativity and Their Care Solutions/Practice Innovations -- Sanofi announced today the launching of the Care Challenge program. Care Challenge (http://www.care-challenge.com) is an online initiative developed by Sanofi in collaboration with nurses' ...

  • 07.07.2011 – 18:17

    Sanofi Pasteur and Merck Vaccines Appoint Dr Jean-Paul Kress, as President of Sanofi Pasteur MSD

    Lyon, France (ots/PRNewswire) - - Newcomer's Biopharmaceutical Experience to Further Develop European Joint-Venture - MSD, known as Merck in the United States and Canada , and Sanofi Pasteur, the vaccines division of Sanofi , the two partner companies in Sanofi Pasteur MSD, announce today the appointment of Dr. Jean-Paul Kress as President of Sanofi Pasteur MSD, ...

  • 27.06.2011 – 07:05

    New Data Shows Lantus® Activation of Insulin Receptor Comparable to Human Insulin

    Paris (ots/PRNewswire) - - Human and in vivo Studies Indicate Lantus(R) Metabolites do not ConferCarcinogenic Potential via IGF-1 Receptor Activation Sanofi announced at the 71st American Diabetes Association Scientific Sessions 2011 the results of four studies[1,2,3,4] indicating that the effect of Lantus(R) (insulin glargine) metabolites on the IGF-1 receptor is ...

  • 27.06.2011 – 07:03

    Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction

    Paris (ots/PRNewswire) - Sanofi announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus(R) and/or Apidra(R) with the insulin delivery device SoloSTAR(R) experienced greater treatment satisfaction, better quality of life and lower fear of hypoglycemia vs those using a premixed insulin product. The goal ...

  • 23.02.2011 – 10:54

    Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event

    LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011 (ots/PRNewswire) -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group , today will participate in the first international bell-ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and future challenges in the battle to eradicate polio at the stock ...

  • 21.02.2011 – 14:03

    Sanofi Pasteur and International Vaccine Institute Partner Against Dengue

    Lyon, France (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group , announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health ...

  • 05.11.2010 – 09:05

    Sanofi-aventis Partners in European Atrial Fibrillation Research Consortium

    Paris, November 5 (ots/PRNewswire) - Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the "European Network for Translational research in Atrial Fibrillation" (EUTRAF), which has been awarded a EUR12 million grant to engage in atrial fibrillation (AF) research. The European consortium is ...

  • 04.11.2010 – 07:02

    Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development

    Lyon, France, November 4 (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group , announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate(1,2), entered its first phase 3 clinical study in Australia. This study is ...